Ki Chung to Neoplasms
This is a "connection" page, showing publications Ki Chung has written about Neoplasms.
Connection Strength
0.372
-
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology. 2011; 81(2):65-72.
Score: 0.171
-
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021 10 01; 27(19):5236-5247.
Score: 0.086
-
A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers. Oncologist. 2021 09; 26(9):e1499-e1507.
Score: 0.083
-
Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007 Jul 01; 25(19):2691-5.
Score: 0.032